Evidence map›Paper›PMID 39836705›Full record

ArticlePLoS biology2025

Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasion.

Harriet V Mears, George R Young, Theo Sanderson, Ruth Harvey, Jamie Barrett-Rodger, Rebecca Penn, Vanessa Cowton, Wilhelm Furnon, Giuditta De Lorenzo, Margaret Crawford and 17 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Evolution of a fuzzy ribonucleoprotein complex in viral assembly.bioRxiv : the preprint server for biology · 2025
    Article
  11. Highly Recurrent Multinucleotide Mutations in SARS-CoV-2.Molecular biology and evolution · 2025
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Harriet V MearsRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID https://orcid.org/0000-0003-0300-0885
George R YoungRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID https://orcid.org/0000-0002-1203-588X
Theo SandersonMalaria Biochemistry Laboratory, The Francis Crick Institute, London, United Kingdom.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
Jamie Barrett-RodgerRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.
Rebecca PennRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.
Vanessa CowtonMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Wilhelm FurnonMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Giuditta De LorenzoMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Margaret CrawfordGenomics STP, The Francis Crick Institute, London, United Kingdom.
Daniel M SnellGenomics STP, The Francis Crick Institute, London, United Kingdom.
Ashley S FowlerGenomics STP, The Francis Crick Institute, London, United Kingdom.
Anob M ChakrabartiRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.
Saira HussainRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.
Ciarán GilbrideRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.
Edward EmmottCentre for Proteome Research, Department of Biochemistry, Cell and Systems Biology, Institute of Systems Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-3239-8178
Katja FinsterbuschImmunoregulation Laboratory, The Francis Crick Institute, London, United Kingdom.
Jakub LuptakMRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
Thomas P PeacockDepartment of Infectious Disease, St Mary's Hospital, Imperial College London, London, United Kingdom.
Jérôme NicodGenomics STP, The Francis Crick Institute, London, United Kingdom.ORCID https://orcid.org/0000-0003-2459-3480
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Massimo PalmariniMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Emma WallCrick/UCLH Legacy Study, The Francis Crick Institute, London, United Kingdom.
Bryan WilliamsUniversity College London and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, United Kingdom.
Sonia GandhiNeurodegeneration Biology Laboratory, The Francis Crick Institute, London, United Kingdom.
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
David L V BauerRNA Virus Replication Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID https://orcid.org/0000-0003-3052-0368

Funding

Medical Research Council MR/W005611/1Medical Research Council MR/Y004205/1Wellcome Trust CC1283Wellcome Trust CC2166
6 · The paper itself

Abstract

Coronaviruses express their structural and accessory genes via a set of subgenomic RNAs, whose synthesis is directed by transcription regulatory sequences (TRSs) in the 5' genomic leader and upstream of each body open reading frame. In SARS-CoV-2, the TRS has the consensus AAACGAAC; upon searching for emergence of this motif in the global SARS-CoV-2 sequences, we find that it evolves frequently, especially in the 3' end of the genome. We show well-supported examples upstream of the Spike gene-within the nsp16 coding region of ORF1b-which is expressed during human infection, and upstream of the canonical Envelope gene TRS, both of which have evolved convergently in multiple lineages. The most frequent neo-TRS is within the coding region of the Nucleocapsid gene, and is present in virtually all viruses from the B.1.1 lineage, including the variants of concern Alpha, Gamma, Omicron and descendants thereof. Here, we demonstrate that this TRS leads to the expression of a novel subgenomic mRNA encoding a truncated C-terminal portion of Nucleocapsid, which is an antagonist of type I interferon production and contributes to viral fitness during infection. We observe distinct phenotypes when the Nucleocapsid coding sequence is mutated compared to when the TRS alone is ablated. Our findings demonstrate that SARS-CoV-2 is undergoing evolutionary changes at the functional RNA level in addition to the amino acid level.

Indexed as

COVID-19Genome, ViralImmune EvasionRNA, ViralSARS-CoV-2Evolution, MolecularGenetic FitnessHumansOpen Reading FramesRegulatory Sequences, Nucleic AcidSpike Glycoprotein, CoronavirusRNA, ViralSpike Glycoprotein, Coronavirus

Identifiers

PMID39836705
PMCPMC11774490

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.